Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.50 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.50 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.50 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.50 |
| ▸ | PRKAG3 | Q9UGI9 | 1/20 | 0.50 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 0.50 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.50 |
| ▸ | HTR7 | P34969 | 1/20 | 0.40 |
| ▸ | LDHA | P00338 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | HTR1A | P08908 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7114723 | 0.85 | KDM4E (0.48) | HPGDKDM4EALDH1A1HTR1ADRD2 | |
| SCHEMBL6626738 | 0.85 | KDM4E (0.48) | HPGDKDM4EALDH1A1HTR1ADRD2 | |
| SCHEMBL4226542 | 0.84 | PRKAB2 (0.63) | HPGDKDM4EALDH1A1PRKAB2PRKAG1 | |
| SCHEMBL9378081 | 0.84 | PRKAB2 (0.47) | HPGDKDM4EALDH1A1PRKAB2PRKAG1 | |
| SCHEMBL4222577 | 0.79 | KDM4E (0.41) | HPGDKDM4EALDH1A1PRKAB2PRKAG1 | |
| SCHEMBL5809840 | 0.79 | KDM4E (0.41) | HPGDKDM4EALDH1A1PRKAB2PRKAG1 | |
| SCHEMBL13056378 | 0.77 | KDM4E (0.43) | HPGDKDM4EALDH1A1PRKAB2PRKAG1 | |
| SCHEMBL15758912 | 0.77 | PRKAB2 (0.48) | HPGDKDM4EALDH1A1PRKAB2PRKAG1 | |
| SCHEMBL13799415 | 0.77 | PARP1 (0.51) | HPGDKDM4EALDH1A1HTR7HTR1A | |
| SCHEMBL5794998 | 0.77 | DRD2 (0.46) | HPGDKDM4EALDH1A1PRKAB2PRKAG1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7435837-B2 | Dihydrobenzofuranyl alkanamine derivatives and methods for using same | WYETH (US) | 2008-10-14 | — | — | US | disclosed |
| EP-1874750-A1 | DIHYDROBENZOFURANYL ALKANAMINE DERIVATIVES AS 5HT2C AGONISTS | Wyeth Incoporated (US) | 2008-01-09 | — | — | EP | disclosed |
| WO-2007030150-A1 | DIHYDROBENZOFURANYL ALKANAMINE DERIVATIVES AS 5HT2C AGONISTS | WYETH (US) | 2007-03-15 | — | — | WO | disclosed |
| EP-1675840-A1 | DIHYDROBENZOFURANYL ALKANAMINE DERIVATIVES AS 5HT2C AGONISTS | Wyeth a Corporation of the State of Delaware (US) | 2006-07-05 | — | — | EP | disclosed |
| US-20050261347-A1 | Dihydrobenzofuranyl alkanamine derivatives and methods for using same | WYETH (US) | 2005-11-24 | — | — | US | disclosed |
| US-20050143452-A1 | Dihydrobenzofuranyl alkanamine derivatives and methods for using same | WYETH (US) | 2005-06-30 | — | — | US | disclosed |
| WO-2005044812-A1 | DIHYDROBENZOFURANYL ALKANAMINE DERIVATIVES AS 5HT2C AGONISTS | WYETH A CORPORATION OF THE STATE OF DELAWARE (US) | 2005-05-19 | — | — | WO | disclosed |
| EP-0428437-B1 | 1,2-Benzisoxazole derivatives, process for their preparation and pharmaceutical compositions containing them | ADIR (FR) | 1994-08-17 | — | — | EP | disclosed |
| US-5134147-A | Antipsychotic agents | ADIR ET COMPAGNIE (FR) | 1992-07-28 | — | — | US | disclosed |
| US-5100902-A | Dopamine and Serotonin Antagonists, Antipsychotic Agents | ADIR ET COMPAGNIE (FR) | 1992-03-31 | — | — | US | disclosed |
| EP-0428437-A1 | 1,2-Benzisoxazole derivatives, process for their preparation and pharmaceutical compositions containing them | ADIR ET COMPAGNIE (FR) | 1991-05-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050143452-A1 | Dihydrobenzofuranyl alkanamine derivatives and methods for using same | HTR2C, HTR1A, HTR3A | HPGD 1445/4885KDM4E 2318/4885ALDH1A1 190/4885 |
| US-20050261347-A1 | Dihydrobenzofuranyl alkanamine derivatives and methods for using same | ADRA2A, HTR2A, ADRA1A | HPGD 2175/4885KDM4E 2246/4885ALDH1A1 283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.